✦ LIBER ✦

Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: The case for continuous antiviral therapy

✍ Scribed by Daniel Shouval; Ching-Lung Lai; Ting-Tsung Chang; Hugo Cheinquer; Paul Martin; Giampiero Carosi; Steven Han; Sabahattin Kaymakoglu; Ricardo Tamez; Joanna Yang; Daniel Tenney; Helena Brett-Smith

Book ID: 116651764
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 269 KB
Volume: 50
Category: Article
ISSN: 0168-8278
DOI: 10.1016/j.jhep.2008.10.017

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Relapse rates in chronic hepatitis B naï

Relapse rates in chronic hepatitis B naïve patients after discontinuation of antiviral therapy with entecavir

✍ Ridruejo, E.; Marciano, S.; Galdame, O.; Reggiardo, M. V.; Muñoz, A. E.; Adrover 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 165 KB

De novo combination of lamivudine and ad

De novo combination of lamivudine and adefovir versus entecavir monotherapy for the treatment of naïve HBeAg-negative chronic hepatitis B patients

✍ Li-Chun Wang; En-Qiang Chen; Jing Cao; Li Liu; Li Zheng; Da-Jiang Li; Lu Xu; Xue 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 243 KB

Efficacy of lamivudine re-treatment for

Efficacy of lamivudine re-treatment for relapsed patients after an initial lamivudine therapy in HBeAg-positive chronic hepatitis B

✍ J. W. Shin; N. H. Park; J. H. Park; J. H. Park; I. D. Jeong; S-J. Bang; K. R. Jo 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB

Sustained viral load and ALT reduction f

Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in HBEAG-negative and -positive patients with chronic hepatitis B who have failed prior lamivudine therapy

✍ R. Gish; T.T. Chang; S. Hadziyannis; J. Cianciara; M. Rizzetto; E. Schiff; G. Pa 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 316 KB

Effect of antiviral therapy on the immun

Effect of antiviral therapy on the immunohistochemical expression of bcl-xL and bax protein in patients with HBeAg-negative chronic hepatitis B

✍ Evangelos Cholongitas; George V. Papatheodoridis; Emanuel K. Manesis; Kaliopi Pe 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 212 KB

## Abstract The effect of antiviral treatment on apoptosis in chronic hepatitis B (CHB) has not been clarified. We evaluated the hepatic immunohistochemical expression of the pro‐apoptotic bax and the antiapoptotic bcl‐xL protein in HBeAg‐negative CHB patients before and after treatment. In our stu

P187 INNATE ANTIVIRAL RESPONSES IN HBeAg

P187 INNATE ANTIVIRAL RESPONSES IN HBeAg NEGATIVE PATIENTS WITH CHRONIC HEPATITIS B (CH-B) UNDER LONG-TERM NUCLEOS(T)IDE ANALOGUE (NUC) TREATMENT: IMPLICATIONS FOR FUTURE IMMUNE THERAPIES

✍ Boni, C.; Lampertico, P.; Talamona, L.; Giuberti, T.; Invernizzi, F.; Schivazapp 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 59 KB